首页> 外文期刊>European Journal of Cancer Supplements >9157 Retrospective review of efficiency of erlotinib or pemetrexed or docetaxel compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy

【24h】

9157 Retrospective review of efficiency of erlotinib or pemetrexed or docetaxel compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy

机译：9157铂类化疗失败后厄洛替尼或培美曲塞或多西紫杉醇与多西他赛相比作为晚期非小细胞肺癌（NSCLC）的后续治疗的效率

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
M.T.Almodovar; A.Luis; M.P.Ferreira; J. Duroda Costa;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. [J] . Ng R, Loreto M, Lee R, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2008,第2期

机译：简要报告：铂类化疗失败后，厄洛替尼或吉非替尼与多西他赛相比作为晚期非小细胞肺癌（NSCLC）后续治疗的疗效的回顾性回顾。
2. 53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin?) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva?) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer [J] . R.Herbst, V.ONeill, L.Fehrenbacher, European Journal of Cancer Supplements . 2006,第12期

机译：53 POSTER A II期，多中心，随机临床试验，评估贝伐单抗（Avastin？）联合化疗（多西他赛或培美曲塞）或盐酸厄洛替尼（Tarceva？）与单纯化疗联合治疗复发或难治性的疗效和安全性非小细胞肺癌
3. 57 Pemetrexed vs docetaxel: a phase III study in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy [J] . C.Manegold, R.Gervais, K.Aigner, European Journal of Cancer Supplements . 2003,第5期

机译：57培美曲塞与多西他赛：一项先前接受过化疗的晚期非小细胞肺癌（NSCLC）患者的III期研究
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
6. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability [O] . Paul Germonpré, Tim Van den Wyngaert 2012

机译：晚期非小细胞肺癌（NSCLC）含培美曲塞的化疗失败后的二线埃洛替尼：实际有效性，安全性和耐受性
7. P3-120: Response rates of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) in clinical practice [O] . Ng Raymond C., Loret Michael, Lee Roy, 2007

机译：P3-120：在临床实践中，厄洛替尼或吉非替尼与多西他赛相比作为晚期非小细胞肺癌（NSCLC）后续治疗的反应率

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号